YBX1 and Hepatic fibrosis: Dooley et  al reported that YB1 exerts anti‐fibrotic action by inhibiting transforming growth factor‐β (TGF‐β) signalling, a major pathway to initiate HSC activation.2 Overexpression of YB1 can partially rescue tissue in a CCl4‐induced liver damage model3 and this beneficial effect is linked with the repressive effect of YB1 on collagen type I gene transcription.4 Furthermore, it is reported that a novel small compound Hsc025 ameliorates CCl4‐induced liver fibrosis in mice by promoting nuclear translocation of YB1 and subsequently inhibiting TGF‐β‐stimulated collagen gene expression.5